Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170006/S039

Avalus Bioprosthesis, Model 400

Medtronic, Inc. · Decision date Oct 23, 2025

FDA DECISIONP170006/S039

What did the FDA decide?

FDA records P170006/S039 as a supplement to PMA P170006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 23, 2025.

FDA approval order statement

modifications to the ethylene oxide sterilization cycle and additional sterilizers for the sub-tier supplier of sterile sutures used in valve assembly
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170006/S039
Regulatory pathway
PMA supplement
Product code
LWR
Decision code
OK30
Decision date
Oct 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: heart-valve, non-allograft tissue.

Product code
LWR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170006/S039 received

    Application receipt date recorded by FDA.

  2. P170006/S039 · FDA decision

    30-Day Notice

  3. P170006/S038 · Related supplement

    Avalus Bioprosthesis, Avalus Ultra Bioprosthesis

  4. P170006/S042 · Related supplement

    Avalus Bioprosthesis Model 400 (40019, 40021, 40023, 40025, 40027, 40029); Avalus Ultra Bioprosthesis Model 400 (400U1

  5. P170006/S044 · Related supplement

    Avalus Bioprosthesis, Model 400

Timeline entries are records held by MedtechLedger for P170006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170006

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 30, 2025FDA
Medtronic, Inc.PMA supplementNov 10, 2025FDA
Medtronic, Inc.PMA supplementFeb 4, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementApr 9, 2026FDA
Medtronic, Inc.PMA supplementJun 1, 2026FDA
Medtronic, Inc.PMA supplementJul 9, 2026FDA

Explore the linked device profile

Other records with product code LWR

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
1851 E. Deere Ave., Santa Ana, CA, 92705

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records